ScholarLens Back to search
2015•Journal of the Renin-Angiotensin-Aldosterone SystemOpen access

Losartan treating podocyte injury induced by Ang II via downregulation of TRPC6 in podocytes

Chi-Xianggeng, Hu-Bo, SY Yu, Yin-Lianghong, Mengyu Mengyu, Wang-Boxun, Yang-Jinsheng, Lin-Jiahui, Huang-Dexu, Chen-lanlan

Open full text 9 citations

Abstract

OBJECTIVE: In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. METHODS: This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression. RESULTS: TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes. CONCLUSION: These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.

About this research paper

What this paper is about

OBJECTIVE: In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. METHODS: This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression. RESULTS: TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes. CONCLUSION: These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. METHODS: This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression. RESULTS: TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes. CONCLUSION: These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.

Key concepts: TRPC6, Podocyte, Losartan, Downregulation and upregulation, Proteinuria, Western blot, Angiotensin II, Nephrin

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Losartan treating podocyte injury induced by Ang II via downregulation of TRPC6 in podocytes — Research Paper | ScholarLens